PSMA & PSA Targeted Therapies for Prostate Cancer Analysed in New Research Report

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new market report.
By: Joe Walsh
 
Jan. 21, 2010 - PRLog -- The report “Competitor Analysis: PSMA & PSA Targeted Therapy” available at http://www.reportbuyer.com/go/LME00102 provides a competitor evaluation in the field of molecules targeting prostate specific membrane antigen (PSMA) or prostate specific antigen (PSA) as of January 2010.

The report gives a compilation of currently active projects in research and development of small molecules, antibodies, proteins, cells and vaccines targeting PSMA or PSA for imaging, treatment and monitoring of cancer. In addition, the report lists company-specific R&D pipelines of PSMA & PSA targeted therapeutics.

Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and is a well-known imaging biomarker for staging and monitoring therapy. PSMA represents an attractive antigen for antibody-based diagnostic and therapeutic intervention in prostate cancer, since it is highly restricted to the prostate and over expressed in all tumour stages.

Prostate-specific antigen (PSA) was discovered more than 20 years ago and has become the premier tumor marker for diagnosis, monitoring and prognosis of prostatic carcinoma despite its very controversially discussed relevance. Similar to PSAM, PSA serves as a molecular target for novel active and passive immunotherapies currently under investigation.

Recently, PSMA has also been found to be expressed in the neovasculature of multiple nonprostatic solid tumours. In addition to the treatment modality antibodies, vaccines including dendritic cell (DC)-based vaccines hold promise as a safe therapy for prostate cancer, and PSMA fulfils the requirements for a tumour-associated antigen to be clinically effective. These findings have spurred development of PSMA-targeted therapies for cancer, and first-generation products have entered clinical testing.

The Biologic and clinical effects were seen in a small fraction of patients and at doses near the maximum tolerated dose. The initial studies provided proof of concept for PSMA-based therapies. New or improved technologies such as antibody-based drug conjugates or dendritic cell based immunotherapies enabled second-generation antibody and vaccine products which have the promise to exploit PSMA for molecularly targeted therapy of prostate and other cancers.

The report “Competitor Analysis: PSMA & PSA Targeted Therapy” is available from Report Buyer at:
http://www.reportbuyer.com/pharma_healthcare/drug_discove...
   
Report Buyer product ID: LME00102   

About Report Buyer.

Report Buyer
http://www.reportbuyer.com/pharma_healthcare/drug_discove... is the independent online store for global business information. The website now lists more than 106,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers. Thousands of professionals from across the world make ReportBuyer.com their first choice in their search for quality business insight.

# # #

Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare.
End
Source:Joe Walsh
Email:***@reportbuyer.com Email Verified
Zip:SE1 3LJ
Industry:Cancer
Location:London City - London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
ReportBuyer PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share